Thiazole‐Semicarbazone Hybrids as Dual‐Stage Inhibitors of Leishmania major Growth: Design, Synthesis, and Mechanistic Insights
Drug Development Research · 2026
DOI: 10.1002/ddr.70275 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Moataz A Shaldam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt. Hauptthemen laut MEDLINE: Leishmania major, Semicarbazones, Antiprotozoal Agents, Thiazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: King Khalid University.
Abstract (Originalsprache)
As a neglected tropical disease, Leishmaniasis continues to pose a serious threat to world health, especially in areas with limited resources. There is a pressing need for safer and more effective antileishmanial drugs due to the limited efficacy, toxicity, and rising resistance of available agents. We report the rational design, synthesis, and biological evaluation of a novel series of 15 hybrid compounds ( 3a‐o ), utilizing the thiazole and semicarbazone pharmacophores, two privileged scaffolds recognized for their wide range of biological activity. Both intracellular amastigote and promastigote forms of Leishmania major were used to test the synthesized compounds' antileishmanial potential. With IC₅₀ values ranging from 2.97 to 10.18 µM against promastigotes and from 3.47 to 12.36 µM against amastigotes, a number of compounds demonstrated greater activity than the reference medication miltefosine. Selectivity indices revealed that compounds 3c , 3d , 3h , and 3i were the most potent, exhibiting a desirable balance between efficacy and cytotoxicity. The robust binding affinities and consistent interactions of these lead compounds inside the PTR1 and DHFR active sites were further supported by in silico docking. In conclusion, this study presents a novel chemotype that shows great promise for future advancement as a potent and focused antileishmanial treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
- Clinical Biochemistry Department, College of Medicine, King Khalid University, Asir, Saudi Arabia.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
- Department of Pharmacology, College of Pharmacy, The Islamic University, Najaf, Iraq.
- Pharmacy Program, Allied Health Department, College of Health and Sport Sciences, University of Bahrain, Zallaq, Bahrain.
ORCID-Profile: Moataz A Shaldam, Haytham O Tawfik, Abdelrahman I Zain-Alabdeen, Rehan Monir, Mohamed R Elnagar, Sherry N Nasralla, Tamer M Ibrahim, Wagdy M Eldehna, Adnan A Bekhit, Heba A Elsebaie
Förderung
- King Khalid University
Zitieren
APA
Shaldam, M. A., Tawfik, H. O., Zain-Alabdeen, A. I., Monir, R., Elnagar, M. R., Nasralla, S. N., Ibrahim, T. M., Eldehna, W. M., Bekhit, A. A., & Elsebaie, H. A. (2026). Thiazole‐Semicarbazone Hybrids as Dual‐Stage Inhibitors of Leishmania major Growth: Design, Synthesis, and Mechanistic Insights. Drug Development Research. https://doi.org/10.1002/ddr.70275
Vancouver
Shaldam MA, Tawfik HO, Zain-Alabdeen AI, Monir R, Elnagar MR, Nasralla SN, et al. Thiazole‐Semicarbazone Hybrids as Dual‐Stage Inhibitors of Leishmania major Growth: Design, Synthesis, and Mechanistic Insights. Drug Development Research. 2026. doi:10.1002/ddr.70275
BibTeX
@article{Shaldam2026,
author = {Shaldam, Moataz A and Tawfik, Haytham O and Zain-Alabdeen, Abdelrahman I and Monir, Rehan and Elnagar, Mohamed R and Nasralla, Sherry N and Ibrahim, Tamer M and Eldehna, Wagdy M and Bekhit, Adnan A and Elsebaie, Heba A},
title = {Thiazole‐Semicarbazone Hybrids as Dual‐Stage Inhibitors of Leishmania major Growth: Design, Synthesis, and Mechanistic Insights},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70275}
}
EUVIMED